- Home
- LSF vs VRCA Comparison
LSF vs VRCA Comparison
Compare LSF & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LSF | VRCA |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.8M | 87.5M |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | LSF | VRCA |
|---|---|---|
| Price | $2.78 | $5.38 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 3 |
| Target Price | $12.00 | ★ $17.00 |
| AVG Volume (30 Days) | 66.9K | ★ 130.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.28 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $43,295,137.00 | N/A |
| Revenue This Year | $15.87 | $372.93 |
| Revenue Next Year | $14.98 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 26.50 | N/A |
| 52 Week Low | $1.98 | $0.39 |
| 52 Week High | $7.94 | $9.82 |
Technical Indicators
Market Signals| Indicator | LSF | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 44.30 | 33.64 |
| Support Level | $2.46 | $5.34 |
| Resistance Level | $2.76 | $6.44 |
| Average True Range (ATR) | 0.22 | 0.47 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 34.68 | 10.24 |
Price Performance
Historical ComparisonAbout LSF Laird Superfood Inc.
Laird Superfood Inc is engaged in the business of manufacturing and marketing differentiated plant-based and functional foods. The product portfolio includes Coffee creamers, Hydration products and beverage-enhancing supplements, Harvest snacks and various other food items, and Coffee, tea, and hot chocolate products.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.